Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.80 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.80 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1859950 | 0.89 | OPRM1 (1.00) | OPRM1OPRL1OPRK1 | |
| SCHEMBL3872453 | 0.82 | OPRM1 (1.00) | OPRM1OPRL1OPRK1 | |
| SCHEMBL1868503 | 0.79 | OPRL1 (0.60) | OPRM1OPRL1OPRK1 | |
| SCHEMBL8446024 | 0.79 | GRIN1 (0.65) | OPRM1OPRL1OPRK1 | |
| SCHEMBL2675276 | 0.78 | OPRM1 (0.70) | OPRM1OPRL1OPRK1 | |
| SCHEMBL3872192 | 0.78 | OPRL1 (0.59) | OPRM1OPRL1OPRK1 | |
| SCHEMBL3873476 | 0.78 | OPRM1 (0.78) | OPRM1OPRL1OPRK1 | |
| SCHEMBL27597318 | 0.78 | OPRM1 (0.58) | OPRM1OPRL1OPRK1 | |
| SCHEMBL3051534 | 0.77 | OPRM1 (0.72) | OPRM1OPRL1OPRK1 | |
| SCHEMBL3871435 | 0.76 | OPRL1 (0.68) | OPRM1OPRL1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253727-A1 | NOCICEPTIN ANALOGS | PURDUE PHARMA L.P. (US) | 2009-10-08 | — | — | US | claimed |
| EP-1997818-A2 | Quinolinone derivatives and their use to treat pain | EURO-CELTIQUE S.A. (LU) | 2008-12-03 | — | — | EP | claimed |
| US-20030013874-A1 | Nociceptin analogs | PURDUE PHARMA L.P | 2003-01-16 | — | — | US | claimed |
| US-20090253727-A1 | NOCICEPTIN ANALOGS | PURDUE PHARMA L.P. (US) | 2009-10-08 | — | — | US | disclosed |
| US-7563809-B2 | Nociceptin analogs | PURDUE PHARMA, L.P. (US) | 2009-07-21 | — | — | US | disclosed |
| EP-1997818-A2 | Quinolinone derivatives and their use to treat pain | EURO-CELTIQUE S.A. (LU) | 2008-12-03 | — | — | EP | disclosed |
| EP-1379252-A4 | NOCICEPTIN ANALOGS | EURO CELTIQUE SA (LU) | 2005-11-02 | — | — | EP | disclosed |
| US-20050148580-A1 | Nociceptin analogs | PURDUE PHARMA L.P | 2005-07-07 | — | — | US | disclosed |
| US-6861421-B2 | Nociceptin analogs | EURO-CELTIQUE S.A (LU) | 2005-03-01 | — | — | US | disclosed |
| EP-1379252-A2 | NOCICEPTIN ANALOGS | Euro-Celtique S.A. (LU) | 2004-01-14 | — | — | EP | disclosed |
| US-20030013874-A1 | Nociceptin analogs | PURDUE PHARMA L.P | 2003-01-16 | — | — | US | disclosed |
| WO-2002085291-A2 | NOCICEPTIN ANALOGS | EURO-CELTIQUE, S.A. (LU) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148580-A1 | Nociceptin analogs | OPRL1, OPRK1, NPBWR1 | OPRM1 4/4885OPRL1 1/4885OPRK1 2/4885 |
| US-20030013874-A1 | Nociceptin analogs | OPRL1, OPRK1, NPBWR1 | OPRM1 5/4885OPRL1 1/4885OPRK1 2/4885 |
| US-20090253727-A1 | NOCICEPTIN ANALOGS | OPRL1, NPBWR1, OPRK1 | OPRM1 5/4885OPRL1 1/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.